false000172312800017231282024-05-022024-05-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 2, 2024
AMNEAL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3848593-4225266
(State or other jurisdiction
of incorporation)		(Commission File Number)(IRS Employer
Identification No.)
400 Crossing Blvd
Bridgewater, NJ 08807
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (908) 947-3120
N/A
(Former Name or Former Address, if Changed Since Last Report) 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: 
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A Common Stock, par value $0.01 per shareAMRX
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.07
Submission of Matters to a Vote of Security Holders.

Amneal Pharmaceuticals, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) on May 2, 2024. Each of the proposals was approved, and each of the director nominees was elected, by the vote of the stockholders at the Annual Meeting as follows:
Proposal 1: To elect the following director nominees to hold office until the 2025 Annual Meeting of Stockholders and until their respective successors are elected and qualified:
 
 
For
 
 
Against
 
 
Abstain
 
 
Broker Non-Votes
 
Emily Peterson Alva
 
 
253,927,467
1,736,375
40,449
24,065,209
 
Deb Autor
 
 
254,054,265



1,609,738


40,288



24,065,209
 
J. Kevin Buchi


253,532,508



2,069,308


102,475



24,065,209

Jeff George
 
 
253,898,828



1,763,854


41,609



24,065,209
 
John Kiely
 
 
253,584,848



2,015,861


103,582



24,065,209
 
Paul Meister
 
 
238,720,752


16,941,409


42,130



24,065,209
 
Ted Nark
 
 
253,943,612



1,499,704


260,975



24,065,209
 
Chintu Patel
 
 
254,283,523



1,100,436


320,332



24,065,209
 
Chirag Patel
 
 
254,065,112



1,379,383


259,796



24,065,209
 
Gautam Patel
 
 
251,712,874



3,732,183


259,234



24,065,209

Shlomo Yanai
 
 
254,374,881



1,067,043


262,367



24,065,209
 

Proposal 2: To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers:
For
 
Against
 
Abstain
 
Broker Non-Votes
254,365,134
1,199,935
139,222
24,065,209

Proposal 3: To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024:
For
 
Against
 
Abstain
 
Broker Non-Votes
279,106,284

624,760
38,456

0






SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 7, 2024AMNEAL PHARMACEUTICALS, INC.
By:/s/ Jason B. Daly
Name:Jason B. Daly
Title:Senior Vice President, Chief Legal Officer and Corporate Secretary


v3.24.1.u1
Document and Entity Information Document
May 02, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 02, 2024
Entity Registrant Name AMNEAL PHARMACEUTICALS, INC.
Entity Central Index Key 0001723128
Entity Emerging Growth Company false
Entity File Number 001-38485
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 93-4225266
Entity Address, Address Line One 400 Crossing Blvd
Entity Address, City or Town Bridgewater
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08807
City Area Code 908
Local Phone Number 947-3120
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Common Stock, par value $0.01 per share
Trading Symbol AMRX
Security Exchange Name NASDAQ
Amneal Pharmaceuticals (NYSE:AMRX)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024 Haga Click aquí para más Gráficas Amneal Pharmaceuticals.
Amneal Pharmaceuticals (NYSE:AMRX)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024 Haga Click aquí para más Gráficas Amneal Pharmaceuticals.